[Congressional Record Volume 162, Number 114 (Thursday, July 14, 2016)]
[Senate]
[Pages S5175-S5176]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




SENATE RESOLUTION 545--SUPPORTING THE DESIGNATION OF JULY 15, 2016, AS 
                    ``LEIOMYOSARCOMA AWARENESS DAY''

  Ms. STABENOW submitted the following resolution; which was considered 
and agreed to:

                              S. Res. 545

       Whereas a soft tissue sarcoma is a rare type of cancer, 
     accounting for approximately 1 percent of newly diagnosed 
     cancers;

[[Page S5176]]

       Whereas Leiomyosarcoma (referred to in this preamble as 
     ``LMS'') is a malignant subtype of soft tissue sarcoma that 
     originates in smooth muscle, often in the walls of blood 
     vessels;
       Whereas LMS is highly aggressive and can be found 
     throughout the body, but is especially concentrated in the 
     uterus, abdominal cavity, and extremities;
       Whereas the National Institutes of Health classifies LMS as 
     a rare disease;
       Whereas most oncologists will only see a few cases of LMS 
     throughout a career;
       Whereas the causes of LMS are still unknown;
       Whereas LMS is largely resistant to standard 
     chemotherapeutic agents, radiation treatment, and current 
     immunotherapies;
       Whereas multidisciplinary care coordination teams, because 
     of their expertise and experience, are critical to the health 
     of LMS patients;
       Whereas LMS research will allow medical professionals to 
     improve the quality of care for LMS patients, lead to better 
     clinical outcomes, and promote longer survival for LMS 
     patients; and
       Whereas increased education and awareness about LMS will 
     contribute to the well-being of the communities of the United 
     States: Now, therefore, be it
       Resolved, That the Senate--
       (1) supports the designation of July 15, 2016, as 
     ``Leiomyosarcoma Awareness Day'';
       (2) recognizes the challenges faced by Leiomyosarcoma 
     patients; and
       (3) commends the dedication of organizations, volunteers, 
     researchers, and caregivers across the country working to 
     improve the quality of life of Leiomyosarcoma patients and 
     the families of Leiomyosarcoma patients.

                          ____________________